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Study objective:We determine whether single-dose oral ondansetron administration to children with vomiting as a result of acute
gastroenteritis without dehydration reduces administration of intravenous fluid rehydration.
Methods: In this 2-hospital, double-blind, placebo-controlled, emergency department–based, randomized trial conducted in
Karachi Pakistan, we recruited children aged 0.5 to 5.0 years, without dehydration, who had diarrhea and greater than or equal to
1 episode of vomiting within 4 hours of arrival. Patients were randomly assigned (1:1), through an Internet-based randomization
service using a stratified variable-block randomization scheme, to single-dose oral ondansetron or placebo. The primary endpoint
was intravenous rehydration (administration of 20 mL/kg of an isotonic fluid during 4 hours) within 72 hours of randomization.
Results: Participant median age was 15 months (interquartile range 10 to 26) and 59.4% (372/626) were male patients.
Intravenous rehydration use was 12.1% (38/314) and 11.9% (37/312) in the placebo and ondansetron groups, respectively (odds
ratio 0.98; 95% confidence interval [CI] 0.60 to 1.61; difference 0.2%; 95% CI of the difference –4.9% to 5.4%). Bolus fluid
administration occurred within 72 hours of randomization in 10.8% (34/314) and 10.3% (27/312) of children administered placebo
and ondansetron, respectively (odds ratio 0.95; 95% CI 0.56 to 1.59). A multivariable regression model fitted with treatment group
and adjusted for antiemetic administration, antibiotics, zinc prerandomization, and vomiting frequency prerandomization yielded
similar results (odds ratio 0.91; 95% CI 0.55 to 1.53). There was no interaction between treatment group and age, greater than or
equal to 3 stools in the preceding 24 hours, or greater than or equal to 3 vomiting episodes in the preceding 24 hours.
Conclusion: Oral administration of a single dose of ondansetron did not result in a reduction in intravenous rehydration use. In
children without dehydration, ondansetron does not improve clinical outcomes. [Ann Emerg Med. 2019;73:255-265.]
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INTRODUCTION
Background
Diarrhea accounts for greater than 500,000 deaths
annually in children younger than 5 years.1,2 A critical
advance has been the introduction of oral rehydration
therapy employing oral rehydration solution. However, oral
rehydration solution use has stagnated in most countries.2
When children in settings with limited health care services
have fluid losses that cannot be replaced orally because of
intractable vomiting, death is a potential outcome. Vomiting
significantly affects oral rehydration therapy success,3 and in
Karachi, Pakistan, 80% of children who develop severe
dehydration have persistent vomiting, with a high frequency
in the first 6 hours of therapy.4 Consequently, antiemetic
administration and antibiotic use are widespread,5 along
with intravenous fluid administration.
Importance
Oral rehydration therapy failures occur primarily because of
persistent vomiting and an inability to drink.6 Consequently,
World Health Organization (WHO) protocols recommend
intravenous fluid therapy administration in such
circumstances, which may divert resources from more needy
patients. An easy-to-administer, effective, safe, and affordable
Volume 73, no. 3 : March 2019 Annals of Emergency Medicine 255
PEDIATRICS/ORIGINAL RESEARCH
Editor’s Capsule Summary
What is already known on this topic
In high-income countries, ondansetron can reduce
intravenous fluid use.
What question this study addressed
In a middle-income country, does oral administration
of a single dose of oral ondansetron reduce the rate of
intravenous fluid administration in children with
vomiting and diarrhea but without dehydration?
What this study adds to our knowledge
In this trial of 626 children, a single dose of oral
ondansetron did not reduce intravenous fluid use. No
serious adverse events were reported.
How this is relevant to clinical practice
Clinicians should not prescribe ondansetron to
vomiting children without evidence of dehydration.
antiemetic agent has the potential to save lives. WHO also
recommends that antiemetics not be given to young
children with diarrhea or dysentery.7 Although older
antiemetic agents had unacceptable adverse effects and
limited efficacy,8 recent research has demonstrated that a
single ondansetron dose can reduce vomiting, intravenous
rehydration use, and hospitalization while improving oral
rehydration therapy efficacy.9-11
Goals of This Investigation
Ondansetron use in low- and middle-income countries
has been evaluated only in small, single-center trials,12-14
and none were designed to answer questions in regard to
intravenous rehydration. Therefore, there remains a need
for definitive evidence to guide ondansetron usage. We
hypothesized that, compared with placebo, single-dose oral
ondansetron administration to children in 2 emergency
departments (EDs) in Pakistan who had vomiting as a
result of acute gastroenteritis would reduce the probability
of receiving intravenous fluid rehydration. In this study, we
included only children without evidence of dehydration15
because we wanted to focus on and be able to analyze
separately a low-risk population.
MATERIALS AND METHODS
Study Design and Setting
Between July 3, 2014, and January 12, 2017, we
conducted a double-blind, placebo-controlled, randomized
superiority trial in the EDs of 2 International Organization
for Standardization–certified Aga Khan institutions in
Pakistan; the University Hospital, Karachi; and the Aga
Khan Hospital for Women and Children, Kharadar,
Karachi. The Aga Khan University Hospital is a 500-bed
hospital, and the ED provides care to approximately
20,000 patients annually. It is the only ED with dedicated
pediatric emergency medicine faculty providing direct
patient care. The Aga Khan Hospital for Women and
Children is a 48-bed hospital for women and children and
includes an ED that is open 24 hours per day, 7 days per
week.
The protocol was approved by the Conjoint Health
Research Ethics Board of the University of Calgary and the
Ethics Review Committee of Aga Khan University,
Pakistan. The trial was reviewed and published as a
summary by The Lancet (protocol 14PRT/2519).
Registration was performed before the enrollment of any
participants.
Selection of Participants
Eligible participants were aged 0.5 to 5.0 years and had
symptoms consistent with gastroenteritis, defined by the
presence of greater than or equal to 1 episode of vomiting
within the 4 hours preceding triage and greater than or
equal to 1 episode of diarrhea during the illness.16 The
minimum age is in keeping with that of previous trials,16
the age at which the smallest study dose (2 mg) could be
administered, and reflects an age below which alternative
diagnoses play a more prominent role. The requirement for
recent emesis was selected to identify children who would
benefit from ondansetron administration during the
encounter. Eligible children had no evidence of
dehydration assessed with the WHO dehydration tool.7
This population was important to study because we
believed they were at lower risk of potential complications
associated with ondansetron administration compared with
children who are dehydrated because the latter group is
more likely to have electrolyte abnormalities and perhaps
more likely to receive intravenous rehydration without a
proper trial of oral rehydration therapy. As such, we did not
want to combine the 2 groups of children into a single trial,
and thus we are currently conducting a clinical trial
evaluating the use of ondansetron in children with evidence
of dehydration in the same milieu (ClinicalTrials.gov
NCT01870648).
We additionally excluded children with any of the
following: bilious or bloody vomiting, hypotension (systolic
blood pressure <70 mm Hg in infants aged 1 to 12
months, <70 mm Hgþ[2age in years] in children aged 1
to 10 years, <90 mm Hg in children 10 years17), weight
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less than 8 kg, vomiting or diarrhea for greater than 7 days,
previous abdominal surgery, known hypersensitivity to
ondansetron or any serotonin-receptor antagonist, personal
or family history of prolonged QT syndrome, receiving a
medication listed as causing torsades de pointes (http://
www.azcert.org/medical-pros/drug-lists/list-01.cfm?
sort¼Generic_name), previously enrolled, and those for
whom follow-up was not possible. Children with
malnutrition (weight for height below –3z scores of the
median WHO growth standards18) were excluded because
of their increased risk of having electrolyte abnormalities.19
A medical officer obtained written informed consent from a
parent or guardian.
Eligible participants were randomized in a 1:1 ratio to
receive a single, weight-based dose of ondansetron
(GlaxoSmithKline, Philadelphia, PA), provided as an oral
disintegrating tablet or placebo (provided in-kind by
GlaxoSmithKline). Patients weighing 8 to 15 kg received a
2-mg dose, and those weighing greater than 15 kg received
4 mg.16 We did not use a milligrams per kilogram dosing
regimen because within the dose range of 0.13 to 0.26 mg/
kg, higher doses of ondansetron do not appear to be superior
to lower ones, nor are they associated with increased adverse
effects.20 The oral disintegrating tablet was placed on the
top of the tongue or along the inner aspect of the buccal
mucosa, and the child was instructed to swallow 5 seconds
later.16 Uncooperative children were assisted by the medical
officer until they swallowed. Oral rehydration therapy began
15 minutes later. Children who vomited within 15 minutes
of medication administration received a second dose.16 The
active and placebo oral disintegrating tablets were identical
in size, appearance, taste, and smell.16 The placebo
contained the inactive ingredients of the active drug:
aspartame, gelatin, mannitol, methylparaben sodium,
propylparaben sodium, and strawberry flavor.
Randomization was stratified by study center and age
(<18 and 18 months), using variable block sizes of 4 to
6. Allocation was concealed through the use of an Internet-
based randomization service (http://www.randomize.net).
A prespecified computer-generated randomization list with
associated kit numbers was sent directly to the University of
Calgary research pharmacist from http://www.randomize.
net through password-protected files. At patient
enrollment, http://www.randomize.net randomly assigned
treatment and then randomly selected a kit number
containing the assigned treatment.
After randomization, the medical officer retrieved the
assigned randomization kit, which contained 2 oral
disintegrating tablets (ie, one extra dose in case of
vomiting). The drugs kits were prepared, packed, and
shipped to study sites in identical containers by the
Research Pharmacy–Alberta Health Services, Calgary Zone,
according to the randomization list. Patients, treating
physicians, investigators, and data assessors were masked to
treatment allocation.
Interventions
After the experimental intervention was provided,
participants received therapy according to WHO standards
of care and as deemed necessary by the emergency
physician. The protocol reinforced the importance of oral
rehydration solution use for the first 4 hours while the child
was monitored and the caregiver was taught how to prepare
and administer oral rehydration solution. The volume
administered was based on the child’s weight,15 and
caregivers were educated on administering a teaspoonful
every 1 to 2 minutes (<2 years) or instructing the child to
sip from a cup (2 years), as appropriate. Breastfeeding
mothers continued whenever the child wanted. Children
were monitored for evidence of deterioration. Caregivers
resumed rehydration 10 minutes after each vomiting
episode. Caregivers were provided with a 2-day oral
rehydration solution supply at discharge.
After discharge, caregivers were instructed to administer
as much fluid as possible to prevent dehydration and to
continue feeding. Exclusively breastfed children were
administered oral rehydration solution in addition to breast
milk. An additional 100 mL of oral rehydration solution
was to be provided for every loose stool.7 Participants
received one zinc tablet (20 mg daily) for 14 days.
Methods of Measurement
While patients were in the hospital, study-funded
medical officers documented the volumes of oral and
intravenous fluids administered, and the frequency and
volumes of vomiting, diarrhea, and urination. Because
separating urine output from stool is challenging in young
children with diarrhea, urine collection bags were provided
for children who were not capable of urinating into
measurement containers. Dehydration parameters and vital
signs were documented at the 4-hour assessment.
Dehydration severity was assessed with the WHO severity
assessment algorithm, which classifies children as having
“some” dehydration if 2 or more of the following are
present: restlessness or irritability, sunken eyes, drinking
eagerly or thirsty, and skin recovers slowly from pinching.7
Caregivers used a diary in which they recorded vomiting
and diarrhea episodes at home. Discharged patients were
reassessed 24-hours after discharge at their home or the
enrolling institution. At the revisit, clinical nurses
determined whether the child required a further ED visit,
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had received intravenous fluid treatment, or had been
hospitalized. If there were no signs of dehydration and
symptoms had subsided, 48- and 72-hour follow-up was by
telephone. For patients with ongoing symptoms or
evidence of dehydration, an in-person 24-hour
reassessment was required. In case of noncompliance,
caregivers were contacted by telephone and information
was gathered in regard to the child’s health and dehydration
severity daily for 7 days. Participating hospital records were
reviewed to confirm caregivers’ reports. If the child was
admitted or received treatment at a different institution,
information was collected from caregivers by telephone.
Outcome Measures
The primary outcome was intravenous rehydration,
defined as the administration of an isotonic fluid at greater
than or equal to 20 mL/kg during 4 hours for the purpose
of rehydration within 72 hours of randomization. This
pragmatic outcome allowed the occurrence of the primary
outcome in children who received maintenance plus
replacement of losses and those who received a fluid bolus
but did not include those who only received antibiotics or
maintenance fluids (eg, 4 mL/kg per hour for those
weighing <10 kg). The 72-hour time frame was selected to
enable a balancing of the potential short-term benefits of
626 Randomized
312 Included in primary analysis
0 Excluded from primary analysis
312 Received allocated treatment 
312 Allocated to Ondansetron 314 Allocated to Placebo
0 Did not receive 
allocated 
intervention
0 Did not receive 
allocated 
intervention
314 Received allocated treatment 
314 Included in primary analysis
0 Excluded from primary analysis
0 Excluded
0 Lost to follow-
up
0 Excluded
0 Lost to follow-
up
2229 Patients assessed for eligibility
1603 Ineligible
784 Some or Severe dehydration
425 Weight < 8kg
138 Previously enrolled
137 Declined to participate
42 Other reasons
26 Bilious or bloody vomitus
16 Symptoms lasting >7days
14 Taking other medications accepted as 
causing Torsades de Pointes
12 Increased risk of prolonged QT 
syndrome
5 Malnutrition (-3z scores of median 
WHO growth standards)
4 Follow-up not possible
Figure 1. Trial profile.
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the intervention (ie, reduction in intravenous line insertion
at the index visit) with the potential adverse effects (ie,
increased diarrhea and revisits).
Secondary endpoints were the presence and frequency of
vomiting during the 4-hour observation period;
hospitalization for greater than 24 hours, defined as ED
arrival until hospital discharge; volume of oral rehydration
solution consumed (milliliters/kilogram) during the 4-hour
observation period; presence of some dehydration during
the 72-hour follow-up period among discharged children;
number of diarrheal stools during the 72-hour follow-up
period; and treatment failure. The latter composite measure
included any of the following: intravenous rehydration as
defined above, nasogastric rehydration for greater than 24
hours, or death within 72 hours.
Exploratory outcomes included serious adverse events,
semi-ICU (for children in shock but not requiring
mechanical ventilation) and ICU admissions, volume of
diarrhea during the 4-hour study period, and 72-hour
hydration status. Parental report was used to identify
delayed serious adverse events.
Primary Data Analysis
The analysis plan for this superiority trial was
prespecified and performed masked to treatment allocation.
The probability that a control arm study participant would
experience the primary outcome measure was estimated
according to data reported by the International Study
Group on Reduced-Osmolarity ORS Solutions (17%).21
In accordance with the former study, investigators with
extensive experience working in the participating EDs
determined that a point estimate of 20% should be used for
the control group. According to the opinion of experts in
the field and our team members who work at the study
sites, the maximum number of patients meeting study
eligibility criteria who should be treated with oral
ondansetron to prevent one failure is 10 (ie, minimum
clinically meaningful difference of 10 percentage points).
We anticipated a 5% loss to follow-up.22 Using a
2-sided type I error of 0.05 and 90% power, the required
sample size was 602 participants. Because of delays in
data entry and data completeness concerns, the
steering committee requested the recruitment of an
additional 25 patients. All randomized children
were included in the analyses, which followed the
intention-to-treat principle.
Patient characteristics are presented as frequencies and
percentages for categorical data and medians (interquartile
range [IQR]) for continuous data. The proportion of
children receiving intravenous rehydration by 72 hours was
analyzed by comparing proportions with a
Mantel-Haenszel test, stratified by clinical center.
Secondary analyses of the primary outcome used a logistic
regression model fitted with treatment group and a priori
identified baseline covariates (antiemetic, antibiotics, zinc
administration prerandomization, and number of vomiting
episodes in the 24 hours before enrollment) that potentially
were associated with the outcome. We conducted
prespecified subgroup analyses based on subject age (ie, <2
years, 2 to 5 years) and presence of the WHO definition of
diarrhea (ie, 3 episodes in a 24-hour period). A post hoc
analysis reanalyzed the primary outcome, including as an
Table 1. Baseline clinical characteristics of participants by
treatment group.
Ondansetron
(n[312)
Placebo
(n[314)
Age, mo 15 (10–25) 16 (11–27)
Male 189 (60.6) 183 (58.3)
Weight, kg 9.7 (8.5–12.0) 10.0 (8.5–11.8)
Chronic medical conditions 1 (0.3) 4 (1.3)
Interval of last vomiting episode
to medication administration, h
1.58 (0.84–2.90) 1.67 (0.92–2.92)
Maximal vomiting episodes per
24-h period
4 (3–6) 4 (3–6)
Vomiting episodes past 24 h 4 (2–6) 4 (2–5)
Vomiting duration, days 1 (1–2) 1 (1–2)
Maximal diarrheal episodes per
24-h period
4 (2–6) 3 (2–6)
Diarrheal episodes past 24 h 3 (1–5) 2 (2–4)
Diarrhea duration, days 1 (1–2) 1 (1–2)
Fever 133 (42.6) 113 (36.0)
Previous ED visit, current illness 41 (13.1) 38 (12.1)
Previous intravenous rehydration,
current illness
17 (5.4) 13 (4.2)
Previous hospitalization, current
illness
3 (1.0) 2 (0.6)
Rotavirus vaccine receive 113 (36.2) 114 (36.3)
Exclusively breastfed 24 (7.7) 19 (6.1)
Triage pulse rate, beats/min 133 (126–146) 132 (122–145)
Triage respiratory rate,
breaths/min
30 (26–32) 30 (26–32)
Triage capillary refill 2 s 5 (1.6) 6 (1.9)
Triage temperature (C/F),
rectal adjusted
37.7 (37.5–38.1)/
99.9 (99.5-100.6)
37.7 (37.5–38.1)/
99.9 (99.5-100.6)
Clinical Dehydration Scale
score33
0 (0–1) 0 (0–1)
Data are presented as No. (%) or median (IQR). Fever was defined as an adjusted rectal
temperature of greater than or equal to 38.0C (100.4F). Axillary and oral temperatures
were adjusted to rectal temperatures by adding 1.1C and 0.6C, respectively.34 Some
children had received more than one medication in the past 24 hours.
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event only patients who experienced the primary endpoint
and developed severe dehydration.
The secondary outcomes of vomiting, hospitalization
greater than 24 hours, development of some dehydration by
72 hours, and treatment failure were analyzed with a Mantel-
Haenszel test stratified by clinical center. The median
differences of the continuous variables vomiting frequency,
volume of oral rehydration solution consumed, and diarrheal
stool frequency were computed with the Hodges-Lehmann
estimator, whereas statistical significance was assessed with a
Van Elteren test stratified by clinical center.
Every effort was made to identify and retrieve complete
data. Missing data were not imputed. A 2-tailed P<.05 was
considered to be statistically significant for the primary
outcome, and a Bonferroni corrected threshold of 0.007 was
used for the 7 secondary outcomes. The analysis was
performed with SPSS (version 22.0; SPSS, Inc., Chicago, IL)
and SAS (version 9.4; SAS Institute, Inc., Cary, NC).
RESULTS
Characteristics of Study Subjects
A total of 2,229 patients were assessed for inclusion and
626 were randomized (Figure 1). Baseline characteristics
were similar in the 2 groups (Table 1). The intervention or
placebo medication administered was vomited by 7 (2.2%)
and 6 (1.9%) children in the ondansetron and placebo
groups, respectively.
Table 2. Participant clinical outcomes by treatment group.
Ondansetron,
N[312
Placebo,
N[314
% Difference
(95% CI)
Median Difference
(95% CI)*
Primary outcome
Intravenous fluids administered, 20 mL/kg 32 (10.3) 34 (10.8) –0.6 (–5.5 to 4.3)
Secondary outcomes, time 0–4 h
Vomiting, yes 61 (19.6) 75 (24.0) –4.3 (–10.8 to 2.1)
Vomiting, frequency 0 (0 to 0) 0 (0 to 0) 0 (0 to 0)
Volume of oral fluids, mL/kg per hour 3.4 (1.9 to 5.7) 3.2 (1.9 to 5.9) 0.2 (–0.4 to 0.4)
Secondary outcomes, time >4 h
Hospitalization >24 h 12 (3.8) 11 (3.5) 0.3 (–2.8 to 3.5)
Presence of some dehydration within 72 h 18 (5.8) 24 (7.6) –1.9 (–5.9 to 2.1)
Diarrhea, frequency during 72 h postenrollment 4 (1 to 7) 4 (1 to 6) 0 (–1 to 0)
Treatment failure 32 (10.3) 34 (10.8) –0.6 (–5.5 to 4.3)
Other outcomes
4-h pulse rate, beats/min 128 (120 to 138) 128 (120 to 136) 0 (–2 to 2)
4-h respiratory rate, breaths/min 30 (26 to 32) 28 (25 to 32) 0 (–2 to 0)
4-h capillary refill 2 s 3 (1.0) 2 (0.6) 0.3 (–1.5 to 2.2)
4-h WHO Dehydration Severity Score
None 305 (97.8) 305 (97.1) 0.6 (–2.1 to 3.4)
Some 7 (2.2) 9 (2.9) –0.6 (–3.4 to 2.1)
Severe 0 0
4-h Clinical Dehydration Scale score33 0 (0 to 0) 0 (0 to 0) 0 (0 to 0)
4-h diarrhea, volume, mL/kg per hour 2.5 (0.0 to 5.0) 2.5 (0.0 to 2.5) 0 (0 to 0)
4-h vomiting, volume, mL/kg per hour 0 (0 to 0) 0 (0 to 0) 0 (0 to 0)
4-h urine output, volume, mL/kg per hour 0.79 (0.44 to 1.78) 0.63 (0.30 to 1.61) –0.01 (–0.20 to 0)
4-h disposition
Discharge 292 (93.6) 288 (91.7) 1.9 (–2.3 to 6.1)
Ongoing observation/oral rehydration 9 (2.9) 11 (3.5) –0.6 (–3.6 to 2.3)
Intravenous rehydration 11 (3.5) 15 (4.8) –1.3 (–4.6 to 2.0)
Discrete variables are provided as No. (%) and continuous variables are presented as median (IQR). Hospital length of stay was defined as a total length of stay from ED arrival
until discharge. Dehydration status was assessed with the WHO dehydration assessment approach.15 Diarrhea was defined as loose or liquid stools.35 Treatment failure was a
composite outcome measure defined by the occurrence of any of the following: intravenous rehydration (20 mL/kg during 4 hours); nasogastric rehydration for greater than 24
hours; and death within 72 hours from any cause, in or out of hospital.
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Main Results
Overall, 12.0% of children (75/626) received
intravenous fluids during the study period (placebo 38/314
[12.1%]; ondansetron 37/312 [11.9%]; odds ratio [OR]
0.98; 95% confidence interval [CI] 0.60 to 1.61;
difference 0.2%; 95% CI of the difference –4.9% to
5.4%). Administration of an isotonic intravenous
rehydration solution at greater than or equal to 20 mL/kg
during 4 hours for the purpose of rehydration within 72
hours of randomization was 10.8% (34/314) in the
placebo group and 10.3% (32/312) in the ondansetron
group (OR 0.95; 95% CI 0.56 to 1.59) (Table 2).
Secondary analysis using a logistic regression model fitted
with treatment group and adjusted for covariates yielded an
OR¼0.94 (95% CI 0.56 to 1.57). Administration of other
antiemetic agents prerandomization was not associated
with the outcome (OR 1.41; 95% CI 0.71 to 2.77)
(Table 3). Inclusion in the regression model of interaction
terms including treatment group and age, presence of
greater than or equal to 3 diarrheal stools in the preceding
24 hours, and presence of greater than or equal to 3
vomiting episodes in the preceding 24 hours did not
significantly alter the results (Table 4). Subgroup analyses
are presented in Figure 2. No study participant developed
severe dehydration.
Overall, 24.0% of children (75/314) in the placebo
group vomited during the 4-hour study observation period
Table 3. Medication administration pre-ED, in the ED, and post-
ED, by treatment group.
Ondansetron
(n[312),
No. (%)
Placebo
(n[314),
No. (%)
Medications administered, past 24 h 90 (28.8) 102 (32.5)
Antacids
Omeprazole/ranitidine 2 (0.6) 5 (1.6)
Antipyretics 32 (10.3) 24 (7.6)
Acetaminophen 26 (8.3) 24 (7.6)
Ibuprofen 6 (1.9) 0
Antibiotics/anthelmintics 31 (9.9) 44 (14.0)
Azithromycin/clarithromycin 4 (1.3) 4 (1.3)
Cefixime/cefotaxime/ceftriaxone 10 (3.2) 12 (3.8)
Diloxanide/mebendazole 2 (0.6) 8 (2.5)
Metronidazole 12 (3.8) 25 (8.0)
Other 8 (2.6) 4 (1.3)
Any antiemetics 48 (15.4) 55 (17.5)
Dimenhydrinate 16 (5.1) 16 (5.1)
Domperidone 33 (10.6) 42 (13.4)
Metoclopramide 1 (0.3) 0
Antihistamines/anticholinergics
Cetirizine/clemastine/
cyclizine/diphenhydramine
4 (1.3) 6 (1.9)
Nutrition
Zinc 9 (2.9) 12 (3.8)
Probiotics
Saccharomyces boulardii 4 (1.3) 9 (2.9)
ED cointerventions
Antacid 10 (3.2) 3 (1.0)
Omeprazole 8 (2.6) 3 (1.0)
Ranitidine 2 (0.6) 0
Antibiotic 56 (18.0) 67 (21.3)
Administered in ED
prerandomization
2 (0.6) 3 (1.0)
Albendazole 1 (0.3) 0
Amoxicillin 0 1 (0.3)
Azithromycin 8 (2.6) 6 (1.9)
Cefixime 11 (3.5) 7 (2.2)
Ceftriaxone 16 (5.1) 27 (8.6)
Ciprofloxacin 4 (1.3) 7 (2.2)
Metronidazole 16 (5.1) 19 (6.1)
Antiemetic
Administered in ED
prerandomization
2 (0.6) 2 (0.6)
Dimenhydrinate 51 (16.3) 59 (18.8)
Domperidone 2 (0.6) 1 (0.3)
Ondansetron 43 (13.8) 52 (16.6)
Antiemetic 6 (1.9) 5 (1.6)
Table 3. Continued.
Ondansetron
(n[312),
No. (%)
Placebo
(n[314),
No. (%)
Antihistamine
Cetirizine 2 (0.6) 2 (0.6)
Antipyretic 44 (14.1) 36 (11.5)
Acetaminophen 33 (10.6) 26 (8.3)
Ibuprofen 11 (3.5) 10 (3.2)
Other
Zinc administered in ED
prerandomization
3 (1.0) 1 (0.3)
Zinc 52 (16.7) 59 (18.8)
S boulardii 89 (28.5) 97 (30.9)
Antibiotic prescribed at/after discharge 53 (17.0) 60 (19.1)
Any antibiotics during the study period 56 (17.9) 67 (21.3)
Fever was defined as an adjusted rectal temperature of greater than or equal to
38.0C (100.4F). Axillary and oral temperatures were adjusted to rectal
temperatures by adding 1.1C and 0.6C, respectively.34 Some children had received
more than one medication in the past 24 hours.
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compared with 19.6% (61/312) in the ondansetron group
(OR 0.77; 95% CI 0.53 to 1.13). There were no
differences in the median number of vomiting episodes
(ondansetron 0, IQR 0 to 0; placebo 0, IQR 0 to 0) or in
the volume of oral fluids consumed (milliliters/kilogram per
hour) (ondansetron 3.4, IQR 1.9 to 5.7; placebo 3.2, IQR
1.9 to 5.9) during the 4-hour study observation period.
The proportions of children hospitalized greater than 24
hours (OR 1.11; 95% CI 0.48 to 2.55) and who developed
some dehydration by 72 hours (OR 0.74; 95% CI 0.39 to
1.39) did not differ between groups. The number of
diarrheal stools during the 72-hour follow-up period was
similar between groups (ondansetron 4, IQR 1 to 7;
placebo 4, IQR 1 to 6). Because no children died and none
received nasogastric rehydration, the composite outcome of
treatment failure was equal to that of intravenous
rehydration. Among patients who had laboratory testing
performed, there were no significant differences (Table 5).
We recorded no serious adverse events or admissions to
the semi-ICU or ICU. Six adverse events were reported in
each study group. No important differences were noted
between groups for type or severity of event. The median
volume of diarrhea during the 4-hour study observation
period was similar between groups (ondansetron 2.5 mL/kg
per hour, IQR 0 to 5.0; placebo 2.5 mL/kg per hour, IQR
0 to 2.5). Last, groups were similar with respect to the
proportion of children who had some dehydration at 72
hours (ondansetron 18/312 [5.8%]; placebo 24/314 [7.6%];
difference 1.9%; 95% CI of the difference –2.1% to 5.9%).
LIMITATIONS
Our study had several limitations. The observed event
rate was lower than anticipated in the control group
(12.1% versus 20%). As a result, the variance of the
observed rates was lower and the power to detect a 10-
percentage-point difference higher. Therefore, we do not
believe this alters our interpretation of our findings, and it
highlights the need to target ondansetron use for children
with evidence of dehydration, failure of oral rehydration
therapy, or recent and significant vomiting.23 Moreover,
despite significant increases in ondansetron use in the
United States during the past decade, intravenous
rehydration rates have not changed significantly.24 Taken
together, these findings highlight the importance of
focusing ondansetron use for children at greatest risk of oral
rehydration therapy failure.
We had intended to collect and perform testing on stool
specimens to determine whether the response varied by
pathogen. However, testing was performed in only 5% of
the sample, and thus valid analyses could not be performed.
In addition, many study participants were coadministered
other medications, including antibiotic and antiemetic
agents including domperidone. Although this was adjusted
for in the analysis and previous studies have not found it to
be an effective antiemetic agent,25 its coadministration may
have played a role in minimizing any effect ondansetron
may have had.
DISCUSSION
Oral administration of a single dose of ondansetron did
not reduce the proportion of children administered
intravenous fluid rehydration in our trial. Analysis of
secondary outcomes, including presence and frequency of
vomiting, hospitalization rate, oral rehydration fluid
volume consumed, development of dehydration, and
diarrheal stool frequency, showed no evidence of benefit
attributable to ondansetron administration. Accounting for
potential risk factors for oral rehydration therapy failure
and intravenous rehydration did not significantly alter
the findings.
Table 4. Multiple regression model of the primary outcome
(intravenous fluids administration, 20 mL/kg, within 72 hours of
randomization), including a priori–identified interaction terms.
Variable OR (95% CI)
Antiemetic in preceding 24 h
Yes 1.58 (0.79–3.15)
No [Reference]
Zinc in preceding 24 h
Yes 0.35 (0.04–2.70)
No [Reference]
Antibiotic in preceding 24 h
Yes 0.90 (0.38–2.11)
No [Reference]
‡3 vomiting episodes in preceding 24 h
Yes 1.13 (0.49–2.62)
No [Reference]
‡3 diarrhea episodes in preceding 24 h
Yes 1.22 (0.59–2.52)
No [Reference]
Age, mo 0.98 (0.95–1.02)
Interaction terms
Treatment groupno. vomiting
episodes in preceding 24 h
0.70 (0.22–2.22)
Treatment groupno. of diarrheal
episodes in preceding 24 h
0.99 (0.35–2.85)
Treatment groupage, mo 0.99 (0.95–1.04)
Model characteristics included the following: omnibus test comparing the fitted model
against the intercept-only model, P¼.76; Nagelkerke R2¼0.022.
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We specifically excluded children with dehydration
because we wanted to focus on a low-risk population;
consequently, the children in our study, compared with
those in previous studies,26 were less unwell. Our findings
similarly differ. A meta-analysis of 3 trials recently reported
a reduction in intravenous rehydration use in patients
treated with ondansetron compared with placebo.27
However, all 3 trials required the presence of dehydration.
Specifically, the 2 studies16,28 performed in the United
States required the presence of mild to moderate
dehydration. The third study, performed in India, required
the presence of some dehydration, but it was the only one
to not report a reduction in intravenous rehydration
rates.12 We enrolled children without dehydration
according to local expert opinion that children without
dehydration might demonstrate symptom progression and
develop dehydration. Thus, through oral rehydration
therapy promotion, early ondansetron administration was
hypothesized to be capable of preventing intravenous
rehydration use. Our findings thus put into context the
clinical features of children unlikely to benefit from
ondansetron administration.
Another key difference from previous studies relates to
the frequency of vomiting. Our eligibility criteria required
greater than or equal to 1 episode of vomiting during the 4
hours preceding triage. Although this criterion has
previously been used,16 the frequency of vomiting in that
study exceeded 9 episodes in the preceding 24 hours,
0% 
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6% 
8% 
10% 
12% 
14% 
All Participants 
(N=626) 
Age < 2 Years 
(N=446) 
≥3 Vomits in 
Preceeding 24 
Hours (N=441) 
≥3 Diarrhea in 
Preceeding 24 
Hours (N=310) 
Received 20ml/kg IVF 
within 72 hours  Ondansetron
Placebo 
Figure 2. Subgroup analyses. IVF, Intravenous fluids.
Table 5. Baseline blood tests.
Ondansetron (N[312) Placebo (N[314)
Mean Difference (95% CI)No. (%) Mean (SD) No. (%) Mean (SD)
Bicarbonate, mmol/L 43 (13.8) 17.3 (4.1) 43 (13.7) 16.6 (3.6) 0.7 (–1.0 to 2.4)
Sodium, mmol/L 42 (13.5) 137.8 (3.8) 45 (14.3) 138.0 (4.0) –0.2 (–1.9 to 1.4)
Potassium, mmol/L 43 (13.8) 4.3 (0.5) 45 (14.3) 4.2 (0.5) 0.08 (–0.1 to 0.3)
Chloride, mmol/L 42 (13.5) 104.1 (5.5) 42 (13.4) 103.4 (4.8) 0.6 (–1.6 to 2.9)
Urea nitrogen, mmol/L 6 (1.9) 15.8 (3.0) 6 (1.9) 9.5 (4.2) 6.3 (1.7 to 11.0)
Creatinine, mmol/L 11 (3.5) 0.44 (0.23) 8 (2.5) 0.34 (0.11) 0.10 (–0.08 to 0.28)
WBC count, 109/L 43 (13.8) 13.5 (6.5) 54 (17.2) 11.8 (4.5) 1.8 (–0.4 to 4.0)
Platelets, 109/L 43 (13.8) 411 (127) 54 (17.2) 412 (156) –1 (–60 to 57)
Hemoglobin, g/L 43 (13.8) 11.3 (1.4) 54 (17.2) 11.2 (1.4) 0.1 (–0.5 to 0.7)
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whereas participants in our study reported just 4 episodes
of vomiting in the preceding 24 hours. Although Roslund
et al28 did not specify a minimum frequency of vomiting
episodes, study participants had a median of 10 episodes
before presentation, with a median duration of vomiting of
1 day in the ondansetron group. Danewa et al12 required a
minimum of 2 episodes of vomiting within the last 6 hours,
and the cohort had a median of 6 episodes. Although our
analysis stratified by frequency of vomiting did not reveal a
significant difference between groups, the low number of
vomiting episodes among participants preceding
enrollment and the low proportion of control participants
who vomited (24%) during the study, compared with
results of previous studies (z35%),16 may further explain
the lack of beneficial effect identified.
As noted, intravenous rehydration use was lower in our
study than we had anticipated. Although that may have
been due to the aforementioned clinical features (ie,
absence of dehydration and fewer vomiting episodes),
ondansetron administration was not our only intervention.
We also ensured that caregivers received education on the
provision of oral rehydration solution, using appropriate
oral rehydration therapy techniques, and they were
provided with zinc therapy, as is recommended by
WHO.29,30 These adjunctive therapies may have played
a role in reducing the frequency of intravenous
rehydration use.
Our findings highlight the adjunctive, and usually not
indicated, use of additional therapies in this population. In
addition to the administration of ondansetron to 50% of
our study population (as per study protocol), 17% of study
participants had received an antiemetic agent before ED
arrival and an additional 36% were administered an
antiemetic agent after enrollment (ie, outside of study
protocol). In the ondansetron study arm, 43 children
(14%) received a second dose of ondansetron while in the
ED despite the responsible physician’s being aware that
they had a 50% chance of already having received a dose of
ondansetron as part of the study protocol. Thus, there is a
clear belief that ondansetron administration is beneficial
when administered to children with mild disease.
We also found antibiotic use to be surprisingly common
both before ED arrival and in the ED itself despite that
international guidelines recommend against antibiotic
treatment for nonbloody diarrhea.31 Our findings are in
keeping with those of other reports, including the recently
completed Malnutrition and Enteric Disease birth cohort
study (2,134 children from 8 sites in Bangladesh, Brazil,
India, Nepal, Pakistan, Peru, South Africa, and the United
Republic of Tanzania) that reported antibiotic use in
44% of cases of nonbloody diarrhea.32
In summary, our findings do not provide evidence to
support the routine administration of a single dose of oral
ondansetron for the prevention of intravenous fluid
administration in children with gastroenteritis but without
evidence of dehydration.
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